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Abstract
After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving
therapy with tyrosine kinase inhibitors develop drug resistance through a variety
of mechanisms. Among these, tumor histology changes are a mechanism of
acquired resistance in epidermal growth factor receptor-mutated and anaplastic
lymphoma kinase-rearranged NSCLC cases. The current availability of therapeu-
tic approaches to overcome tyrosine kinase inhibitor resistance in oncogenic-
driven lung cancers justifies secondary tumor biopsy in these patients. On the
other hand, little is known about the mechanism of disease progression in non-
oncogenic driven NSCLC. Nevertheless, NSCLC lacking “druggable” genetic
alterations are not considered for secondary biopsy, as it is commonly believed
that these tumors cannot develop histologic or molecular changes. Herein, we
report two paradigmatic cases of wild-type NSCLC showing histologic “change”
on secondary biopsy, allowing for a successful switch in therapeutic strategy.
Introduction
Epidermal growth factor receptor (EGFR) and anaplastic
lymphoma kinase (ALK) are the targets of several tyrosine
kinase inhibitors (TKIs), some of them approved for treat-
ment and others currently in clinical development. Usually,
TKI resistance develops after an initial benefit through a
variety of mechanisms. Among these, tumor histology
changes are a mechanism of acquired resistance in EGFR-
mutated and ALK-rearranged NSCLC cases.1–9 The availa-
bility of therapeutic approaches to overcome TKI resist-
ance in oncogenic-driven lung cancers (LCs) justifies
secondary tumor biopsy in these patients.1,3–5,9
However, about 35% of NSCLCs have no driver muta-
tions showing a wild-type genetic set up and as they are
not considered for secondary biopsy (because it is com-
monly believed that they cannot develop molecular
changes), little is known about the mechanism of disease
progression in non-oncogenic driven LC.10
Herein, we report two paradigmatic cases of NSCLC
without driver mutations (wild-type NSCLC) showing his-
tologic “transformation” on secondary biopsy, allowing for
a successful switch in therapeutic strategy. These observa-
tions could suggest the clinical benefit of secondary biopsy
even in this subset of LC lacking “druggable” genetic
alterations.
Patients
Case 1
In August 2012, a 64-year-old, male smoker presented with
chest pain. A computed tomography (CT) scan showed a
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right lung nodule with rib metastasis (stage IV). His carci-
noembryonic antigen (CEA) serum level was 12.5 ng/mL,
while his neuron specific enolase (NSE) level was unre-
markable. Bronchial biopsy revealed an adenocarcinoma. A
multiplex analysis by MALDI-TOF with LungCarta Panel
(Agena Bioscience, Mountain View, CA, USA) yielded no
mutations in EGFR, K-RAS, BRAF and in the other tested
genes (AKT1, ALK, BRAF, DDR2, EGFR, EPHA3, EPHA5,
ERBB2, FGFR4, JAK2, KRAS, MAP2K1 , MET , NOTCH1 ,
NRAS, NRF2, NTRK1, NTRK2, NTRK3, PIK3CA, PTCH1,
PTEN, PTPN11, PTPRD, STK11, TP53). ALK and ROS-1
rearrangement by immunohistochemistry (IHC) and fluo-
rescence in-situ hybridization (FISH) were negative. The
patient received cisplatin/pemetrexed chemotherapy for
four cycles and achieved a partial response (PR). After-
ward, the patient underwent an atypical lung resection with
a concomitant biopsy of the rib lesion. The original histol-
ogy was confirmed. Because the bone lesion was not radi-
cally resected, radiotherapy to the rib (45 Gy) was
performed. Radiological follow-up showed no clear signs of
disease progression during the subsequent three years. In
February 2015, a CT scan showed a significant increase in
the lung lesion with concomitant enlargement of mediasti-
nal lymph nodes. While CEA levels ranged from 2.5 to
5.6 ng/mL, a rapid increase of NSE (25.6 μg/L) was
observed. As a part of re-evaluation work-up, a secondary
bronchial biopsy revealed small cell lung cancer (SCLC).
Based on this data, the patient was treated with four cycles
of carboplatin/etoposide and once again achieved PR
(Fig 1). The patient is still alive after 44 months of
follow-up.
Case 2
In May 2013, a 59-year-old, male smoker presented with
cough and hemoptysis resulting from a mass located in the
right upper lobe and involving hilar lymph nodes. NSE
and CEA serum levels were 14 μg/L and 1.6 ng/mL,
respectively. A bronchial biopsy revealed SCLC (stage
T3N2M0). The patient achieved PR after four cycles of cis-
platin/etoposide and sequential radiotherapy (57.2 Gy).
Eight months later, ground-glass opacity with septal thick-
ening was detected during a CT scan of the right upper
lobe. A slight increase in CEA (13.2 ng/mL) and a decrease
in NSE (8 μg/L) levels were noted. The substantial modifi-
cation of the radiological scenario combined with the fluc-
tuation of serum markers led us to perform a secondary
biopsy. A “wild-type” adenocarcinoma with lymphangitic
spread was diagnosed. Molecular and immunohistochem-
ical analyses were completely negative for targetable muta-
tions. The patient commenced a second-line regimen with
carboplatin/pemetrexed (six cycles) followed by mainte-
nance with pemetrexed (three cycles, then halted as per the
patient’s wishes), and achieved PR (Fig 2). No peculiar tox-
icity was reported from the second-line treatment. The
patient is alive and well after 36 months of follow-up.
Discussion
Histologic transformation is a well-known phenomenon
underlying acquired resistance to TKI in oncogenic-driven
LC.1 However, histologic transformation may be an
acquired mechanism to chemotherapy resistance, even in
non-oncogenic driven LC. A possible explanation of this
phenomenon is the transformation of NSCLC to SCLC,
and vice versa. A second possibility is the presence of com-
bined NSCLC and SCLC histology ab initio, also found in
wild-type carcinomas. This phenomenon is possibly under-
estimated because of a lack of robust data supporting a sec-
ondary biopsy practice at disease progression in wild-type
LC. In addition, pathological and molecular results from a
secondary biopsy were obtained through a small fragment
of tissue instead of surgical resection, which could intro-
duce a sampling bias error because of the small amount of
material. However, we hypothesized that a higher but still
unknown percentage of advanced non-operable LC cases
Figure 1 Case 1 clinical course including computed tomography (CT)
scans, tumor histology on biopsy, serum tumor markers, and treatment
history. The CT scan showed a peripheral lung nodule with irregular
margins of the right upper lobe, consistent with an invasive adenocarci-
noma (ADC) at histology. The carcinoembryonic antigen (CEA) serum
level was 12.5 ng/mL (normal value <5 ng/mL), while the neuron spe-
cific enolase (NSE) level was unremarkable. Chemotherapy with cisplati-
num (Cis) plus pemetrexed (Pem) was performed for four cycles.
Three years later, a chest CT scan revealed a central lesion with
enlargement of the mediastinal lymph nodes, corresponding to small-
cell lung cancer (SCLC) associated with an increased NSE level (25.6 μg/
L; normal value <12 μg/L). The therapeutic strategy was altered to a
chemotherapy regimen with carboplatinum (Carbo) plus etopo-
side (Eto).
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were histologically heterogeneous, consisting of NSCLC
associated with an SCLC component, in comparison with
surgically resected cancers where the rate of major histo-
logic heterogeneity is only 4% for NSCLC and 9–26% for
SCLC. If the hypothesis is correct, the therapeutic strategy
should be able to target one of the components, leading to
the selective growth of the other.1,4 Again, in the well-
known setting of oncogenic-driven LC, several cases of
mixed EGFR-mutated NSCLC/SCLC have been reported,
suggesting a degree of plasticity between the two histotypes
in some cases, without the selective pressure of TKIs. One
of the main molecular mechanisms necessary for transdif-
ferentiation of adenocarcinoma cells to neuroendocrine
cells is the loss of RB1, which always occurs during the
transformation of EGFR-mutated NSCLC to SCLC. How-
ever, further studies are necessary to identify the mechan-
isms of progression, histologic transformation, and
molecular change in wild-type LC, which have not yet been
investigated.1,8–10
Modifications of some ancillary findings during disease
course may be a reliable predictor of histologic change:
clinical course, serum tumor marker levels (CEA, NSE),
and imaging pattern.5,6 Although guidelines do not recom-
mend the use of tumor markers in diagnosis or follow-up,
a careful examination of the fluctuation of NSE and CEA
levels, coupled with modifications of the radiologic pattern
of the tumor should be considered as possible predictors of
histologic change in “non-druggable” LC. Some authors
have also suggested the potential clinical significance of
pro-gastrin-releasing-peptide as a tumor marker for the
early prediction of disease transformation from adenocarci-
noma to SCLC.9
Clinical course, fluctuation of serum tumor marker
levels (CEA, NSE) and changes in imaging pattern repre-
sent key findings in suspected histologic transformation,
even in wild-type LC. Secondary tumor biopsy in these
cases seems appropriate, as histologic transformation sig-
nificantly alters treatment recommendations because
patients may have a surprisingly prolonged course of dis-
ease as a result of the effective selection of histology-driven
chemotherapy.
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